US-based biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) and French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the European Commission has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils.
Dupixent is the first-ever targeted therapy for COPD. It targets adults with eosinophilia, a specific type of white blood cell, who are already on standard-of-care inhaled medications.
This approval is based on positive Phase 3 trials showing significant reductions in exacerbations, improved lung function and better health-related quality of life. Dupixent is the sixth approved use for the drug in the EU and represents a new treatment option for an estimated 220,000 patients. Regulatory submissions are ongoing in other regions.
Dupixent is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study